What We Do


NanoValent is advancing a new generation of Targeted Nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) IP technology. These TNS may provide a vast improvement over current treatment options including chemotherapy, antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by truly targeting and optimising the delivery of emerging candidates including biologicals, small molecules and nucleic acid based therapeutics.

Our current main candidate focus is in oncology with our lead candidate NV103 (Irinotecan-anti-CD99) approaching potential IND status with strong data in CD99 expressing tumor models including Glioblastoma, Pancreatic, Ovarian and Ewing Sarcoma. However, it is already clear, that once clinically validated, TNS technology can be applied to other oncology challenges plus, due to their capacity to cross the blood brain barrier (BBB) other non-oncological sectors such as neurology. We also have other candidates such as NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and a rapidly progressing pilot program in nucleic acid delivery.

Our Technology

NVP uses its HPLN IP to develop targeted nanosphere (TNS) based products because HPLN represent a unique new nanoparticle encapsulating and payload control platform also able to harness genuine antibody and peptide based targeting to tumor and other specific cell surface antigens. Also, unlike other supposedly targeted technologies, the ‘payload’ can be more easily user selected, including proven cytotoxics, nucleic acid based entities or small molecules, or even any mixture thereof. HPLN technology is subject to broad patent control by NVP.

HPLN have already enabled various TNS candidates but longer term we believe that via collaborative programs we can apply the platform to other targeting species, including bispecific targeting, as well as further payloads allowing use with other malignancies and other therapeutic or even diagnostic opportunities outside oncology.

Why is the TNS approach unique?


We already have excellent chemotherapeutic compounds and rich knowledge in their everyday use, plus emerging tumor-specific biologicals. However, we believe our TNS approach will:

– Improve both efficacy and practical utility of existing agents in existing settings

– Broaden use of existing as well as new cancer drugs

– Improve management of toxicity

– Improve scheduling practicalities with treatments

– Develop innovative or enhanced methods of delivering potential new entities or treatments via TNS either in oncology or other therapeutic areas